Drug Trial Radar · NCT07221734
Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
632
Planned (sponsor's estimate)
Start
Dec 29, 2025
Primary completion
Apr 2027
Study completion Feb 2029
Sponsor
- Lead sponsor
- mAbxience Research S.L.Industry
- Sponsor type
- Industry
- First posted
- Oct 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomised, multicentre, multinational, double-blind, integrated study to sompare the pharmacokinetics, efficacy, safety, and immunogenicity of MB11 versus Opdivo® in subjects with previously untreated advanced (unresectable or Metastatic) Melanoma
Conditions
- Advanced (Unresectable or Metastatic) Melanoma
Interventions
MB11 (Proposed Nivolumab Biosimilar)Drug
During fist 12 cycles: 3 mg/kg IV infusion, over 30 minutes, Q2W. On Cycle 13 onwards: 3 mg/kg IV infusion, over 30 minutes, Q2W or 240 mg flat dose Q2W dosing
EU-Opdivo®Drug
During fist 12 cycles: 3 mg/kg IV infusion, over 30 minutes, Q2W. On Cycle 13 onwards: 3 mg/kg IV infusion, over 30 minutes, Q2W or 240 mg flat dose Q2W dosing
US- sourced Opdivo®Drug
During fist 12 cycles: 3 mg/kg IV infusion, over 30 minutes, Q2W. On Cycle 13 onwards: 3 mg/kg IV infusion, over 30 minutes, Q2W or 240 mg flat dose Q2W dosing
Primary outcomes
What the sponsor says the trial is designed to measure.
- To demonstrate the Pharmacokinetic (PK) bioequivalence between MB11 and EU/ US-Opdivo.Time frame: Week 1 - Week 24
- To demonstrate the efficacy equivalence of MB11 and Opdivo® administered as first-line treatment in adult subjects with untreated, unresectable, or metastatic Stage III or Stage IV melanomaTime frame: Week 1 - Week 24
Locations
86 sites in 13 countries. Site status is shown where the registry gives one.
Site 102002
Banja Luka, Bosnia and Herzegovina · Recruiting
Site 102001
Sarajevo, Bosnia and Herzegovina · Recruiting
Site 102003
Zenica, Bosnia and Herzegovina · Recruiting
Site 103009
Barretos, Brazil · Recruiting
Site 103007
Belo Horizonte, Brazil · Recruiting
Site 103008
Belo Horizonte, Brazil · Recruiting
Site 103002
Bento Gonçalves, Brazil · Recruiting
Site 103014
Blumenau, Brazil · Recruiting
Site 103012
Caxias do Sul, Brazil · Recruiting
Site 103004
Ijuí, Brazil · Recruiting
Site 103013
Jaú, Brazil · Recruiting
Site 103015
Lajeado, Brazil · Recruiting
Site 103010
Natal, Brazil · Recruiting
Site 103001
Porto Alegre, Brazil · Recruiting
Site 103011
Ribeirão Preto, Brazil · Recruiting
Site 103018
Rio de Janeiro, Brazil · Recruiting
Site 103017
Santa Cruz do Sul, Brazil · Recruiting
Site 103005
São Caetano do Sul, Brazil · Recruiting
Site 103016
São Paulo, Brazil · Recruiting
Site 103006
Sorocaba, Brazil · Recruiting
Site 104002
Independencia, Chile · Recruiting
Site 104004
La Florida, Chile · Recruiting
Site 104003
Providencia, Chile · Recruiting
Site 104005
Providencia, Chile · Recruiting
Site 104001
Viña del Mar, Chile · Recruiting
Site 105002
Batumi, Georgia · Recruiting
Site 105001
Tbilisi, Georgia · Recruiting
Site 105003
Tbilisi, Georgia · Recruiting
Site 105004
Tbilisi, Georgia · Recruiting
Site 106001
Efkarpia, Greece · Recruiting
Site 107002
Catanzaro, Italy · Recruiting
Site 107001
Siena, Italy · Recruiting
109003
Arequipa, Peru · Recruiting
109001
Lima, Peru · Recruiting
109002
Lima, Peru · Recruiting
109004
Lima, Peru · Recruiting
109005
Trujillo, Peru · Recruiting
Site 111003
Funchal, Portugal · Recruiting
Site 111001
Lisbon, Portugal · Recruiting
Site 111002
Lisbon, Portugal · Recruiting
Showing 40 of 86 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.